This article is more than 5 years old. Information may no longer be current.

EYEGUARD-B study reaches target exacerbation event

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The phase 3 EYEGUARD-B study of gevokizumab reached its target exacerbation event, according to a Xoma press release.

The EYEGUARD-B study is a randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s disease uveitis. The study is sponsored by Servier, the release said.

The objective was to demonstrate the superiority of gevokizumab compared with placebo in reducing the risk of Behçet’s disease uveitis exacerbations and to assess the safety of gevokizumab. Patients with a history of Behçet’s disease uveitis with ocular involvement of the posterior segment who had experienced a recent ocular exacerbation were randomized to receive a 60-mg dose of gevokizumab or placebo once a month in addition to immunosuppressant therapy and oral corticosteroids.

The time to the first acute ocular exacerbation is the primary endpoint of the study.

Servier is closing the clinical database and analyzing the data from this part of the study. The trial is ongoing and remains double-masked. Servier expects primary endpoint results in about 7 weeks, the release said.